IRIS
VICECONTE, GIULIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.559
NA - Nord America 1.936
EU - Europa 1.430
SA - Sud America 256
Continente sconosciuto - Info sul continente non disponibili 81
AF - Africa 71
OC - Oceania 5
Totale 6.338
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.833
SG - Singapore 1.001
RU - Federazione Russa 668
CN - Cina 624
VN - Vietnam 401
IT - Italia 323
BR - Brasile 201
HK - Hong Kong 172
DE - Germania 109
BD - Bangladesh 98
FR - Francia 89
NL - Olanda 70
JP - Giappone 57
KR - Corea 56
GB - Regno Unito 55
CA - Canada 50
IN - India 46
MX - Messico 28
FI - Finlandia 27
AR - Argentina 21
PL - Polonia 21
ZA - Sudafrica 20
CI - Costa d'Avorio 13
ID - Indonesia 13
PH - Filippine 13
SE - Svezia 12
AT - Austria 11
IQ - Iraq 11
EC - Ecuador 10
MA - Marocco 10
PK - Pakistan 10
UA - Ucraina 10
CL - Cile 9
EG - Egitto 7
SA - Arabia Saudita 7
IE - Irlanda 6
TH - Thailandia 6
TR - Turchia 6
VE - Venezuela 6
ES - Italia 5
JM - Giamaica 5
TW - Taiwan 5
AE - Emirati Arabi Uniti 4
AZ - Azerbaigian 4
CO - Colombia 4
JO - Giordania 4
KE - Kenya 4
NI - Nicaragua 4
CH - Svizzera 3
ET - Etiopia 3
LT - Lituania 3
PA - Panama 3
TN - Tunisia 3
TT - Trinidad e Tobago 3
UZ - Uzbekistan 3
AL - Albania 2
AU - Australia 2
BG - Bulgaria 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
MK - Macedonia 2
MY - Malesia 2
NZ - Nuova Zelanda 2
OM - Oman 2
SY - Repubblica araba siriana 2
AO - Angola 1
BE - Belgio 1
BO - Bolivia 1
BW - Botswana 1
BY - Bielorussia 1
CV - Capo Verde 1
DJ - Gibuti 1
GD - Grenada 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
IR - Iran 1
KY - Cayman, isole 1
KZ - Kazakistan 1
LC - Santa Lucia 1
LU - Lussemburgo 1
LV - Lettonia 1
LY - Libia 1
MN - Mongolia 1
NG - Nigeria 1
NP - Nepal 1
PE - Perù 1
PT - Portogallo 1
PW - Palau 1
PY - Paraguay 1
QA - Qatar 1
RO - Romania 1
RS - Serbia 1
SC - Seychelles 1
SD - Sudan 1
Totale 6.249
Salva come PNG Salva come JPEG
Città #
Singapore 522
San Jose 351
Hefei 288
Ashburn 265
Moscow 174
Hong Kong 164
Ho Chi Minh City 134
Naples 133
Beijing 118
Los Angeles 91
Hanoi 82
Council Bluffs 73
Santa Clara 72
Chandler 67
The Dalles 67
New York 57
Amsterdam 52
Tokyo 51
Seoul 49
Lauterbourg 43
Dallas 36
Munich 30
São Paulo 29
Frankfurt am Main 25
Montreal 22
Orem 20
Redondo Beach 20
Da Nang 18
Buffalo 17
Haiphong 17
Warsaw 17
Nuremberg 16
Seattle 15
Atlanta 14
Boston 14
Milan 14
Millbury 14
Phoenix 14
Brooklyn 13
Houston 13
Mexico City 13
Chicago 12
Guangzhou 12
Lawrence 12
Stockholm 12
Turku 12
Denver 11
Des Moines 11
London 11
Rome 11
Toronto 11
Rio de Janeiro 9
Boardman 8
Can Tho 8
Chaozhou 8
Helsinki 8
Johannesburg 8
Kochi 8
Baghdad 7
Casablanca 7
Charlotte 7
Lappeenranta 7
Querétaro 7
Biên Hòa 6
Bologna 6
Chennai 6
Dublin 6
Falkenstein 6
Fisciano 6
Hải Dương 6
Paris 6
Poplar 6
Washington 6
Wilmington 6
Bengaluru 5
Brasília 5
City of London 5
Düsseldorf 5
Guarulhos 5
Kronberg 5
Manchester 5
Napoli 5
Ottawa 5
Porto Alegre 5
Richmond 5
San Francisco 5
Amman 4
Baku 4
Bắc Ninh 4
Cairo 4
Dhaka 4
Florence 4
Guayaquil 4
Hưng Yên 4
Managua 4
Marseille 4
Minneapolis 4
Orlando 4
Parma 4
Philadelphia 4
Totale 3.633
Salva come PNG Salva come JPEG
Nome #
Correction: Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case–control study (SAVALO Study)(BMC Infect Dis., (2024), 24, 1434, 10.1186/s12879-024-10303-5) 188
Efficacy of Molnupiravir in Reducing the Risk of Severe Outcomes in Patients with SARS-CoV-2 Infection: A Real-Life Full-Matched Case–Control Study (SAVALO Study) 178
Hepatitis C screening in the Emergency Department of a large hospital in southern Italy: results of a pilot study 176
Invasive Fungal Infections in Hospitalized Patients with COVID-19: A Non-Intensive Care Single-Centre Experience during the First Pandemic Waves 167
A Simple Non-Invasive Score Based on Baseline Parameters Can Predict Outcome in Patients with COVID-19 162
Casirivimab and Imdevimab for Pregnant Women Hospitalized for Severe Coronavirus Disease 2019 (COVID-19) 158
Diabetes and COVID-19: The potential role of mTOR 156
Pneumocystis jirovecii pneumonia in an immunocompetent patient recovered from COVID-19 154
Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single-centre study 153
COVID-19 chest CT and laboratory features of B.1.617.2 (Delta variant) vs B.1.1.7 (Alpha variant) surge: a single center case-control study 151
Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study (Journal of Neurology, (2022), 269, 6, (3301-3307), 10.1007/s00415-022-11009-x) 149
Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity—LINA cohort) 148
Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study 147
Impact of oral antiviral therapy against HCV on gut microbiota. A prospective study 142
COVID-19 in patients with thymic epithelial tumors with or without Good's syndrome: a single-center retrospective study 142
Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence: Results from an Italian real-life cohort (LINA cohort) 142
Epidemiological and clinical features of syphilis in the 21st century: A seven-year observational retrospective study of outpatients 140
Risk of invasive fungal infections among patients treated with disease modifying treatments for multiple sclerosis: a comprehensive review 140
Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis 138
Microbiota and hepatitis C virus in the era of direct-acting antiviral agents 134
Risk Factors for Pneumocystis jirovecii Pneumonia in Non-HIV Patients Hospitalized for COVID-19: A Case-Control Study 134
COVID-19 Post-Exposure Evaluation (COPE) Study: Assessing the Role of Socio-Economic Factors in Household SARS-CoV-2 Transmission within Campania Region (Southern Italy) 134
Update on infective complications in patients treated with alemtuzumab for multiple sclerosis: review and meta-analysis of real-world and randomized studies 134
Pneumocystis jirovecii Pneumonia in Non-HIV Patients Recovering from COVID-19: A Single-Center Experience 133
Sotrovimab in Solid Organ Transplant Patients With Early, Mild/Moderate SARS-CoV-2 Infection: A Single-center Experience 133
Invasive pulmonary aspergillosis and pulmonary tuberculosis in a patient treated with infliximab for Crohn's disease 133
Prevalence of Pneumocystis jirovecii Colonization in Non-Critical Immunocompetent COVID-19 Patients: A Single-Center Prospective Study (JiroCOVID Study) 132
Seronegative occult HBV reactivation complicated with fulminant acute liver failure after rituximab for chronic inflammatory demyelinating polyneuropathy 132
Optimizing COVID-19 treatment in immunocompromised patients: early combination therapy with remdesivir, nirmatrelvir/ritonavir and sotrovimab 130
Treatment of Carbapenem-Resistant Acinetobacter baumannii in Real Life (T-ACI): A Prospective Single-Center Observational Study 129
Appropriateness of antibiotic prescription for targeted therapy of infections caused by multidrug-resistant bacteria: Assessment of the most common improper uses in a tertiary hospital in Southern Italy 129
Casirivimab/imdevimab + remdesivir in hospitalized patients with severe Covid-19: A single centre experience 128
Case Report: Discovery a Novel SARS-CoV-2 Variant in a Six-Months Long-Term Swab Positive Female Suffering From Non-Hodgkin Lymphoma 123
Should SARS CoV-2 infection be considered an independent risk factor for Pneumocystis jirovecii pneumonia? Emerging data after two years of pandemic from a single center experience 122
Home parenteral nutrition in patients with intestinal failure: Possible undetected complications 118
Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis 117
Monoclonal antibodies for mild-to-moderate COVID-19 in multiple sclerosis: A case series 116
Chest CT in COVID-19 patients: structured vs conventional reporting 114
Outpatient Use of Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Mild-to-Moderate Coronavirus Disease 2019 106
Caspofungin for Primary Antifungal Prophylaxis in Acute Myeloid Leukemia: A Real-Life Study from an Academic Center 105
Management of hepatitis B virus (HBV) infection in multiple sclerosis patients on disease modifying therapies (DMTs) 101
Long-term oritavancin therapy for shoulder prosthetic joint infection: A case guided by therapeutic drug monitoring (TDM) 99
Salvage Therapy with Rezafungin for Candida parapsilosis Spondylodiscitis: A Case Report from Expanded Access Program 96
Toxoplasma Gondii Replication During Belatacept Treatment in Kidney Transplantation: A Case Report and a Review of the Literature 91
COVID-19, SARS and MERS: are they closely related? 88
Long-term Safety and Effectiveness of Rezafungin Treatment in Candidemia and Invasive Candidiasis: Results From an Early Access Program in Italy and Germany 69
Epidemiology and pathogenesis of fulminant viral hepatitis in pregnant women 68
Covid-19 R0: Magic number or conundrum? 67
Pneumocystis jirovecii pneumonia in COVID-19: an overlooked clinical entity—Response to “Pneumocystis pneumonia risk among viral acute respiratory distress syndrome related or not to COVID 19” 55
Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study) 37
Totale 6.338
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.334
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.334
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202297 0 0 0 0 1 8 3 3 0 10 38 34
2022/2023256 14 14 10 8 35 35 12 27 38 48 13 2
2023/2024275 9 40 38 22 32 48 4 27 5 4 31 15
2024/20251.587 35 24 3 20 54 97 139 92 88 191 586 258
2025/20263.881 377 407 454 459 592 159 386 213 323 235 116 160
2026/2027185 54 125 6 0 0 0 0 0 0 0 0 0
Totale 6.338